Compare AbCellera Biologics Inc (ABCL) vs SPDR Gold Trust (GLD) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

GLD trades at $382.13, up 1.06% with a bearish technical signal from moving averages. Recent news highlights central bank gold purchases and analyst price targets near $4,600 per ounce for physical gold. The fund shows strong annual returns of 22.27% but faces resistance near $383-$387 levels amid mixed oscillators.

Outlook remains cautiously optimistic with institutional demand supporting prices, though technical resistance and Fed policy uncertainty pose near-term risks. Long-term bullion fundamentals appear intact, but volatility may persist around key economic data releases.